GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Neuraxis Inc (AMEX:NRXS) » Definitions » EBIT per Share

Neuraxis (Neuraxis) EBIT per Share : $-2.28 (TTM As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Neuraxis EBIT per Share?

Neuraxis's EBIT per Share for the three months ended in Mar. 2024 was $-0.32. Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $-2.28.

During the past 3 years, the average EBIT per Share Growth Rate was -38.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Neuraxis's EBIT per Share or its related term are showing as below:

NRXS' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -38.8   Med: -38.8   Max: -38.8
Current: -38.8

During the past 4 years, the highest 3-Year average EBIT per Share Growth Rate of Neuraxis was -38.80% per year. The lowest was -38.80% per year. And the median was -38.80% per year.

NRXS's 3-Year EBIT Growth Rate is ranked worse than
86.23% of 1300 companies
in the Biotechnology industry
Industry Median: 3.4 vs NRXS: -38.80

Neuraxis's EBIT for the three months ended in Mar. 2024 was $-2.07 Mil.

Neuraxis EBIT per Share Historical Data

The historical data trend for Neuraxis's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neuraxis EBIT per Share Chart

Neuraxis Annual Data
Trend Dec20 Dec21 Dec22 Dec23
EBIT per Share
-0.68 -0.49 -0.52 -2.85

Neuraxis Quarterly Data
Dec20 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EBIT per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.11 -0.19 -0.96 -0.81 -0.32

Neuraxis EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Neuraxis's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

EBIT per Share(A: Dec. 2023 )
=EBIT/Shares Outstanding (Diluted Average)
=-9.269/3.252
=-2.85

Neuraxis's EBIT per Share for the quarter that ended in Mar. 2024 is calculated as

EBIT per Share(Q: Mar. 2024 )
=EBIT/Shares Outstanding (Diluted Average)
=-2.072/6.551
=-0.32

EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.28

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neuraxis  (AMEX:NRXS) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Neuraxis EBIT per Share Related Terms

Thank you for viewing the detailed overview of Neuraxis's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Neuraxis (Neuraxis) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Neuraxis Inc (AMEX:NRXS) » Definitions » EBIT per Share
Comparable Companies
GTBP ALZN VIRI EDSA VYNE ARAV OGEN DOMH TNXP NHWK OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
N/A
Address
11550 N. Meridian Street, Suite 325, Carmel, IN, USA
Website
http://www.neuraxis.com
Neuraxis Inc is a growth stage company focused on developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology.
Executives
Masimo Corp 10 percent owner 52 DISCOVERY, IRVINE CA 92618
John G Seale officer: CHIEF FINANCIAL OFFICER 10038 OXFORD PIKE, BROOKVILLE IN 47012
Brian Allen Carrico director, officer: CEO, DIRECTOR 11550 NORTH MERIDIAN STREET, SUITE 325, CARMEL IN 46032
Christopher Robin Brown director, officer: DIRECTOR OF INNOVATION 829 S. ADAMS ST, VERSAILLES IN 47042
Daniel Jerome Clarence officer: CHIEF OPERATING OFFICER 10461 W GRANDVIEW DRIVE, COLUMBUS IN 47201
Thomas Joeseph Carrico officer: CHIEF REGULATORY OFFICER 829 S. ADAMS ST., VERSAILLES IN 47042
Gary Merril Peterson officer: DIR.OF DESIGN & ENGINEERING 829 S. ADAMS ST., VERSAILLES IN 47042
Bradley Mitchell Watkins director 10322 MEDICIS PLACE, WELLINGTON FL 33449
Jane Elizabeth Keyser director 220 VIRGINIA AVENUE, INDIANAPOLIS IN 46204
Timothy Robert Henrichs director 324 LEITCH AVENUE, LA GRANGE IL 60525
Adrian Miranda officer: Chief Medical Officer, SVP 829 S. ADAMS STREET, VERSAILLES IN 47042